Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.
Longitudinal, cas-control study, observational multicenter study based on a cohort of 200
SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the
COVID-RIC-1 cohort.
The follow-up the persistence of SARS-CoV-2 serological status for 2 years in 200 patients
with inflammatory rheumatisms compared to matched 100 healthy controls to evaluate the impact
of immuno-suppressive therapy will be proposed.
Schedule: 4 visits over a 24-month period.
An observational routine care study was initiated in 16 French hospitals to assess the
SARS-CoV-2 seroprevalence in France in a population with CIRs (Covid-RIC-1). The project
plans to screen 5000 CIRs patients. The COVID-RIC-2 study will thus be proposed to these
pre-screened subjects according to their positive status in the serology for SARS-CoV-2 at
the time of their inclusion in COVID-RIC-1.
For the control group, 100 health professionals participating in the COVID-BIOTOUL cohort
will be selected to be matched on age, gender, and the time between the date of infection
with Covid-19 and the first serology of CIR patients.
Biological: Biological samples
Serum and plasma samples. At baseline, 6, 12 and 24 months
Inclusion Criteria:
- Patients with rheumatoid arthritis or spondyloarthritis
- With positive serology for SARS-CoV-2 infection less than 3 months old at the time of
inclusion
- Under biotherapy, or conventional synthetic Disease-modifying antirheumatic drugs
(csDMARD) or Nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids for at least
one month during the year 2020
- Agreeement to participate two years in the study
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Refusal to participate in the study
Centre hopsitalier universitaire de Montpellier
Montpellier, Occitanie, France